Upgrade your career with IPI - Training Courses for Industry Professionals

Graeme Ladds, Director of PharSafer, has over 30 years’ experience working in the pharmaceutical industry. Having started his career at Ashbourne Pharmaceuticals in 1989 as Head of Drug Safety & Medical Information, he went on to become Head of Global Pharmacovigilance at Shire Pharmaceuticals. He then set up his consultancy and specialist CRO company, PharSafer Associates Ltd, where he has been involved in establishing pharmacovigilance in companies, performing audits across Europe and the USA, SOP writing, acting as QP for companies, and helping with regulatory inspections.

Sayed K Goda, a biochemistry and drug discovery professor, has a robust academic background. He earned a BSc in Chemistry and an MSc in organic chemistry from Cairo University, Egypt. He then pursued a PhD in Biochemistry from the University of Southampton, UK. Recognising the pivotal role of technology management in his field, he obtained an MBA in technology management from the Open University, UK, in 2000. His diverse educational background equips him with a unique perspective and a broad range of skills, making him a valuable asset in the field of biochemistry and drug discovery.

After completing his PhD, Sayed embarked on a leadership journey at the Porton Down establishment in Salisbury, UK, where he served for fourteen years as a senior scientist and a team leader. During that time, he led commercial and medically sensitive research. He employed protein engineering to produce novel commercially and medically important proteins. 

In 2002, Sayed's academic prowess and leadership skills led him to a professor position at Cairo University, Egypt. His tenure was marked by transformative contributions, notably the establishment of a new BSc Biotechnology program. He also supervised many successful MSc and PhD degrees.

In 2006, Dr. Goda accepted a professor position at Qatar University, Qatar, where he taught many major courses in biochemistry and biotechnology and successfully obtained many research grants.

In 2012, Sayed's expertise and reputation led him to a senior scientist and Professor position at the Antidoping laboratory in Qatar. He led research in various fields and established a protein engineering laboratory here. His exceptional ability to secure research funds, totalling over two million, for cancer-targeting drug discovery projects. His collaboration with Groningen University, Netherlands, resulted in the successful completion of four Ph. Ds and numerous publications, further solidifying his status as a prolific researcher.

Sayed has years of commercial and medical research experience in a conventional research institute in the UK.

He is also a regular reviewer for many high-impact journals, and he is currently a guest editor for Cancers.   

Ed Jordan is a dynamic keynote speaker and seasoned executive and leadership coach, with over 10 years' experience empowering leaders and organisations to reach their full potential. After 25 years as a TV and radio presenter, multi-platinum recording artist and film composer in South Africa, he joined the corporate sector in 2014 and gained significant experience in financial services, specifically in innovation, wealth and high net worth private banking. He’s worked in 16 countries across the African continent as well as London, Jersey and the Isle of Man.

Ed is now based in the UK and specialises in transformational leadership, executive development, and corporate communication coaching. He is is passionate about inspiring change and fostering growth by delivering engaging keynotes and customized coaching solutions that drive performance and success. 

Rupert Hawke, founder of Hawke Legal, has a business degree and is a qualified management accountant. He spent the first 10 years of his career working in multi-national business. In 2007 he was appointed Finance Director of Cartwright King Solicitors – then a regional East Midlands firm. Firstly as FD and then as Managing Director (appointed 2013), Rupert oversaw CK’s journey to becoming a national law firm with 18 offices nationwide offering a wide range of legal services and renowned for a great culture, quality staff, and cutting edge IT systems.

Through his wide-ranging managerial experience in the legal sector, Rupert is a leading authority on law firm financial / strategic management and its application, and has contributed to numerous publications and spoken widely including for The Law Society.

After 12 years at Cartwright King Rupert decided he wanted a new challenge and started Rupert Hawke Legal – a consultancy that utilises the mass of experience and contacts Rupert has developed in his leading role in the legal sector.

Arun Singh (Prof) OBE, FRSA is an international lawyer and consultant to an international law firm. He was formerly a partner and head of commercial law at KPMG Legal and partner at Masons (now Pinsent Masons).

Arun has advised on disputes and collaborations in a wide range of jurisdictions including Europe, countries in West and East Africa, India, Bangladesh, China, Hong Kong, Saudi Arabia, UAE, Qatar, Pakistan, Libya, Jordan, Syria, the US, Caribbean, Russia, Israel, Lebanon, Egypt, Thailand and Singapore. Arun is cited and ranked in the Chambers Guide to the world’s leading lawyers. He concentrates on international investment, joint ventures, licensing of technology, research and development, M&A, energy, outsourcing and corporate governance in developed and emerging markets; he also handles international legal risk management matters. Arun advises a range of international organisations and is a visiting professor in International Business, Leadership and Negotiations at Salford University Business School, senior associate at Oxford University’s Institute of Legal Practice and teaches international leadership and negotiations at the University of Cambridge. He has facilitated programmes in Europe, Asia, the Middle East and the US.

He is a recognised corporate educator and a non-executive director of two international investment companies – one of which is listed on the London Stock Exchange, chairing the Audit Committee and Investment Committee.

He was appointed an OBE by HM the Queen in January 1999 for services to international trade, investment and intercultural management. Arun is an editor and contributor to a number of publications including Business and Contract Law (a Thorogood Special Report) and How to Lead Smart People – Leadership for Professionals (Profile Books), a facilitator for company programmes and an experienced speaker at international corporate conferences.

Jonathan Hughes, Ph.D., FTOPRA, has over 35 years of worldwide regulatory and clinical affairs experience across medical devices, drug / biologic – device combination products and in-vitro diagnostics. He has worked with medical device and pharmaceutical companies, both large and small, across multiple locations to help develop and execute regulatory strategies for market clearance, approval and access.

Jonathan has hands-on experience in a variety of therapeutic areas and has worked across different technologies and types of medical products including medicated devices (devices containing ancillary drug and biologic constituents), drug delivery systems and componentry, sterile and non-sterile disposables and durable equipment, in-vitro diagnostics, software controlled devices and standalone software (including mobile apps). He has experience of regulating medical devices and combination products across most international markets including the European Union, US, Japan, China, Canada and Australia.

Jonathan specialises in regulatory strategy, regulatory and clinical development pathways, worldwide regulatory submissions and training. He has a strong knowledge of quality management systems and has direct hands-on experience of US FDA, MDSAP, EU NB, Brazilian ANVISA and Chinese NMPA inspections. He has worked with all the major international regulatory agencies, in particular (multiple) Notified Bodies and US FDA, EU Competent Authorities, Japanese PMDA, Chinese NMPA.

Jonathan has served on two European Commission Expert Working Groups on the Drug / Device Borderline and Device Classification. He is a Fellow of the regulatory professional organisation, TOPRA, and is a regular contributor on numerous educational and training programmes. Jonathan has registered teacher status at Cranfield University, is a Visiting Industrial Fellow at the University of Hertfordshire and also a visiting lecturer at University of Newcastle upon Tyne.

In 2003 David established PharmaDelivery Solutions Ltd as a specialised consultancy service in the field of drug delivery combination products (especially respiratory) device technology. This has led to involvement in projects with focus in pulmonary, nasal and other delivery routes, with an international client base. Much of the activity of PharmaDelivery Solutions Ltd is focused in the area of development programme support, regulatory GAP analysis and generation of documentation supporting development and test programmes, together with data review and contingency evaluation.

David has over 35 years experience in the development, industrialization and approval of inhalation drug delivery systems, combination products and medical devices.

PharmaDelivery Solutions Ltd has provided input ranging from GAP analysis and comment to complete remedial implementation in areas including

• Design Control
• Risk Management
• Materials strategies
• Regulatory documentation
• Technical reviews and opinion

In addition to activities supporting commercial organizations, David has been involved in the following roles;

Honorary Teaching Fellow in the School of Pharmacy and Pharmaceutical Sciences at the University of Manchester and is author/ tutor for the Pharmaceutical Industry Advanced Training (PIAT) MSc module on Inhalation dosage forms.

A UK national expert representing the British Standards Institute on ISO TC84 developing new international standards for pulmonary and nasal delivery devices syringes and catheters.

David has also worked with the United Nations and various national governments to develop and establish transition strategies from the use of CFC in Metered Dose Inhalers and to secure appropriate budgets from the Multi-lateral fun for the implementation of the Montreal Protocol in emerging markets around the world.

Alex Evans is a pharmacist with over a decade of pharmacy practice experience. His first job was floating for a chain community pharmacy, before managing long-term care, community, and hospital outpatient pharmacies.

He also served as a pharmacy project manager for Ascension Health, where he helps with implementing new service lines, accreditation and licensing, revenue cycle, and the standardizing of operations across all retail pharmacies. 

Alex has precepted and guest lectured at the University of Hawaii at Hilo (UH-Hilo) pharmacy school and precepted students from University of Florida, Florida A&M University, University of South Florida, and Nova Southeastern University. 

He is the founder of PharmCompliance.com, a site dedicated to helping pharmacists better understand compliance and operations. He is also a strong supporter of Dispensary of Hope and the recipient of their Network Ambassador Award. He received the Introductory Pharmacy Practice Experience (IPPE) Preceptor of the Year award in 2012 from UH-Hilo.

Alex currently works as an independent medical writer and is a regular contributor for GoodRx and AchieveCE. He has written for numerous websites, trade magazines, and professional societies, including the National Psoriasis Foundation, Carlat Psychiatry Report, Guideline Central, CE Impact, and Pharmacy Times.

With over thirty years’ experience of working in and with the public, corporate, and charitable sectors, Claire has expertise in providing strategic, analytical, emotionally intelligent solutions that engender, inform, facilitate and embed growth through compassionate leadership.

Extending from post-doctoral studies on neurology, specifically the link between emotional intelligence and cognitive intelligence, Claire has written, presented, and worked at a national, European, and international level and has published several research papers and books.

In her previous time as a CEO of various charities, she has practical experience in the art of compassionate leadership and has developed a real passion for helping individuals and organisations to optimise their growth potential.

In addition to her work as a facilitator, delivering sessions and presenting, Claire also works as an independent consultant providing emotionally intelligent strategic solutions, embedding compassionate leadership and maximising growth.

In her spare time, Claire runs for mental health and wellbeing, including running marathons and ultra marathons.

Dr Cheryl L Barton is an independent consultant with over 35 years' research and business analysis experience. Following her senior research positions in academia and seven years with Merck, in which she was responsible for a variety of CNS research projects. Dr Barton joined Dutch investment bank ABN Amro NV as a senior equity analyst to provide coverage on pan-European companies and assessed the potential impact of new drug development on European Stocks. In 2002, Dr Barton founded PharmaVision to provide independent, tailor-made, life science and consumer health research to pharmaceutical companies, competitive intelligence specialists, investment institutions, and healthcare communication agencies. Dr. Barton regularly writes articles for Pharmtech regarding the latest advances in scientific technologies and regulatory issues that impact the Biopharma and MedTech industries.